Plenary Speaker

Ron Wange, PhD

Principal Consultant @ Aclairo Pharmaceutical Development Group

Title TBA

Jenna Moccia, PhD

Director, Product Management,Epithelial and Pluripotent Stem Cell Biology @ STEMCELL Technologies

Intestinal and Hepatic Organoid Systems: In Vitro Models of Drug Toxicity

Sophie Tourdot, PhD

Immunogenicity Sciences Lead @ Pfizer

Hapten/ADA response and state of ADA in tox - Title TBA

Russell Naven, PhD

Head, Predictive Safety Data Exploration @ Novartis

BAPTG in AI prediction of Tox using computational methods - title TBA

Matt Wagoner, PhD

Global Head of Investigative Toxicology @ Takeda Pharmaceuticals

Predicting DILI with AI Transcriptomics - Title TBA

Radhakrishna Sura, PhD, DABT, DACVP

Senior Director, Nonclinical Safety and Pathobiology @ Gilead Sciences, Inc.

New Approach Methodologies (NAMs): Role of Nonclinical Scientists

Zhechu Peng, PhD, DABT

Director Project Toxicologist Immune Safety @ AstraZeneca

in vitro only toxicology package for a T-cell engagers across 2 indications - title TBA

Giel Hendriks, PhD

CEO @ Toxys Inc.

Use of NAM's for endocrine disruptor and DART Assessment - tentative title

Kim Rockley

 @ AconiX

Benefits of Early In Vitro Screening for Seizure Liability in Problem Solving and Decision Making

Kaushik Datta, PhD, DABT

Distinguished Scientist and Therapeutic Area Lead @ Merck

IQ DruSafe survey: NHP use in oncology tox packages (supporting 3Rs)

Petra Lutterbuese, PhD

Principal Scientist @ Amgen (Munich)

BiTE platform reducing NHP use - title TBA

Sheroy Minocherhomji, PhD

Senior Director, Nonclinical Safety and Toxicology @ Eli Lilly

Nonclinical Developmental Considerations of RNA-based Complex Biologics

Rhiannon Hardwick, PhD, DABT

Scientific Director, Discovery Toxicology @ Bristol Myers Squibb 

tox strategies /in vitro species selection and off-target profiling and how that leads into in vivo PD profiling and off-target assessment - title TBA

Wei Wang, PhD, DABT

Director @ Eli Lilly

tox profiles of GLP-1 agonists and oral peptides - Title TBA

John Vahle, PhD, DVM

Senior Research Fellow @ Eli Lilly

evolution of safety strategy over past decade - title TBA

Marie Lemper, PharmD, PhD, DABT, ERT, MSc

Head of US Toxicology @ UCB

Title TBA